Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AEHA Aesther Healthcare Acquisition	$9.96	$10.25	$8.20 ▼ $14.22	$131.78M	0.04	434,237 shs	1.29 million shs
COGT Cogent Biosciences	$7.07 -2.3%	$5.63	$3.72 ▼ $12.61	$824.32M	1.82	1.31 million shs	1.51 million shs
KROS Keros Therapeutics	$13.65 -0.4%	$14.11	$9.12 ▼ $72.37	$556.84M	1.31	859,847 shs	360,018 shs
SBTX Silverback Therapeutics	$16.78 +1.3%	$14.44	$2.80 ▼ $8.97	$605.05M	0.6	337,931 shs	1.94 million shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AEHA Aesther Healthcare Acquisition	0.00%	0.00%	0.00%	0.00%	+0.01%
COGT Cogent Biosciences	-0.28%	-4.99%	+50.21%	+11.90%	-18.56%
KROS Keros Therapeutics	-0.36%	+1.86%	-5.90%	+24.52%	-70.50%
SBTX Silverback Therapeutics	+4.87%	+9.30%	+10.61%	+26.01%	+102.82%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AEHA Aesther Healthcare Acquisition	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
COGT Cogent Biosciences	1.4738 of 5 stars	3.4	3.0	0.0	0.0	0.0	0.0	0.6
KROS Keros Therapeutics	3.5508 of 5 stars	4.3	3.0	0.0	0.0	0.0	5.0	0.6
SBTX Silverback Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AEHA Aesther Healthcare Acquisition	0.00	N/A	N/A	N/A
COGT Cogent Biosciences	2.75	Moderate Buy	$14.57	106.10% Upside
KROS Keros Therapeutics	2.50	Moderate Buy	$30.56	123.85% Upside
SBTX Silverback Therapeutics	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest AEHA, KROS, SBTX, and COGT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/17/2025	COGT Cogent Biosciences	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
6/10/2025	KROS Keros Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$32.00 ➝ $18.00
5/30/2025	KROS Keros Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$15.00
5/29/2025	COGT Cogent Biosciences	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$21.00 ➝ $25.00
5/20/2025	COGT Cogent Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$14.00 ➝ $12.00
5/12/2025	KROS Keros Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Outperform ➝ Sector Outperform	$41.00 ➝ $26.00
5/8/2025	KROS Keros Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$40.00 ➝ $25.00
5/7/2025	COGT Cogent Biosciences	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$8.00 ➝ $7.00
4/9/2025	KROS Keros Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$43.00 ➝ $25.00
4/1/2025	KROS Keros Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$15.00 ➝ $15.00
4/1/2025	KROS Keros Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$40.00 ➝ $40.00

(Data available from 6/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AEHA Aesther Healthcare Acquisition	N/A	N/A	N/A	N/A	($0.14) per share	N/A
COGT Cogent Biosciences	N/A	N/A	N/A	N/A	$1.32 per share	N/A
KROS Keros Therapeutics	$3.55M	156.19	N/A	N/A	$14.11 per share	0.97
SBTX Silverback Therapeutics	N/A	N/A	N/A	N/A	$7.41 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AEHA Aesther Healthcare Acquisition	-$560K	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
COGT Cogent Biosciences	-$255.86M	-$1.84	N/A	N/A	N/A	N/A	-149.79%	-75.61%	8/5/2025 (Estimated)
KROS Keros Therapeutics	-$187.35M	-$0.18	N/A	N/A	N/A	1.96%	0.75%	0.69%	8/6/2025 (Estimated)
SBTX Silverback Therapeutics	-$89.48M	-$2.42	N/A	∞	N/A	N/A	-29.62%	-28.20%	N/A

Latest AEHA, KROS, SBTX, and COGT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/6/2025	Q1 2025	COGT Cogent Biosciences	-$0.56	-$0.52	+$0.04	-$0.52	N/A	N/A
5/6/2025	Q1 2025	KROS Keros Therapeutics	-$0.01	$3.62	+$3.63	$3.62	$84.62 million	$211.25 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AEHA Aesther Healthcare Acquisition	N/A	N/A	N/A	N/A	N/A
COGT Cogent Biosciences	N/A	N/A	N/A	N/A	N/A
KROS Keros Therapeutics	N/A	N/A	N/A	N/A	N/A
SBTX Silverback Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AEHA Aesther Healthcare Acquisition	N/A	0.29	0.29
COGT Cogent Biosciences	N/A	5.13	5.13
KROS Keros Therapeutics	N/A	19.29	19.29
SBTX Silverback Therapeutics	N/A	67.87	67.87

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AEHA Aesther Healthcare Acquisition	78.64%
COGT Cogent Biosciences	N/A
KROS Keros Therapeutics	71.56%
SBTX Silverback Therapeutics	74.89%

Insider Ownership

Company	Insider Ownership
AEHA Aesther Healthcare Acquisition	19.80%
COGT Cogent Biosciences	7.29%
KROS Keros Therapeutics	20.60%
SBTX Silverback Therapeutics	34.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AEHA Aesther Healthcare Acquisition	2,021	13.23 million	10.61 million	Not Optionable
COGT Cogent Biosciences	80	113.86 million	105.56 million	Optionable
KROS Keros Therapeutics	100	40.62 million	32.25 million	Optionable
SBTX Silverback Therapeutics	83	36.06 million	23.65 million	Not Optionable

AEHA, KROS, SBTX, and COGT Headlines

Recent News About These Companies

Silverback Therapeutics (NASDAQ:SBTX) Trading Up 4.9% - Here's Why

June 25 at 2:20 AM | marketbeat.com

Silverback Therapeutics (NASDAQ:SBTX) Stock Price Down 6.8% - Here's Why

June 3, 2025 | marketbeat.com

Meet the Silverback, the Leader of the Troop

October 17, 2024 | pbs.orgP

10 Fun Facts About Mountain Gorillas

September 18, 2024 | nationalgeographic.comN

CapstanTx secures $165 million to deliver precise in vivo cell engineering

July 28, 2024 | pharmaphorum.comP

ARS Pharmaceuticals Inc (SPRY)

May 11, 2023 | uk.investing.com

Wild Isles

March 12, 2023 | wwf.org.ukW

A look back at RNA Therapeutics – day one

February 23, 2023 | pharmaphorum.comP

SPRY ARS Pharmaceuticals, Inc.

January 24, 2023 | seekingalpha.com

ARS Pharma CEO Richard Lowenthal Holds 8% Silverback Stake After Merger

November 22, 2022 | 247wallst.com

Dr. Sarina Tanimoto Discloses Position in SBTX / Silverback Therapeutics

November 18, 2022 | nasdaq.com

ARS Pharmaceuticals Announces Presentation of Clinical Data Supporting neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (Type I) including Anaphylaxis

November 10, 2022 | finance.yahoo.com

ARS Pharmaceuticals Closes Merger with Silverback Therapeutics

November 8, 2022 | finance.yahoo.com

Silverback : FDA Accepts ARS Pharm's NDA For Neffy For Treatment Of Allergic Reactions

October 28, 2022 | markets.businessinsider.com

FDA accepts ARS Pharma’s NDA for Neffy

October 24, 2022 | thepharmaletter.comT

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates HIL, SBTX, COWN, AERI

October 23, 2022 | kentuckytoday.comK

Silverback Therapeutics, Inc. announces the FDA’s acceptance of ARS Pharmaceuticals’ NDA for neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (type I) including Anaphylaxis

October 21, 2022 | finance.yahoo.com

Is Silverback Therapeutics Inc (SBTX) Stock a Good Investment?

October 19, 2022 | aaii.comA

SHAREHOLDER ALERT: The M&A Class Action Firm is Investigating the Merger – RFP, SBTX, AAWW, COWN

October 12, 2022 | bakersfield.comB

INVESTIGATION ALERT: Halper Sadeh LLC Investigates CVET, SBTX, IRBT

September 17, 2022 | markets.businessinsider.com

SBTX Silverback Therapeutics, Inc.

September 15, 2022 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

AEHA, KROS, SBTX, and COGT Company Descriptions

Aesther Healthcare Acquisition NASDAQ:AEHA

Aesther Healthcare Acquisition Corp. intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses primarily in the pharmaceutical and medical devices sectors. The company was incorporated in 2021 and is based in New York, New York.

Cogent Biosciences NASDAQ:COGT

$7.07 -0.17 (-2.35%)

Closing price 04:00 PM Eastern

Extended Trading

$7.07 0.00 (0.00%)

As of 07:36 PM Eastern

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.

Keros Therapeutics NASDAQ:KROS

$13.65 -0.06 (-0.44%)

Closing price 04:00 PM Eastern

Extended Trading

$13.66 +0.00 (+0.04%)

As of 06:56 PM Eastern

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-012, which is in Phase II clinical trial to treat pulmonary arterial hypertension and cardiovascular disorders; and KER-065 that is in Phase I clinical trial for the treatment of obesity and neuromuscular diseases. In addition, the company has collaboration and license agreement with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize KER-050 and licensed products containing KER-050. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.

Silverback Therapeutics NASDAQ:SBTX

$16.78 +0.21 (+1.27%)

As of 06/24/2025

Silverback Therapeutics, Inc., a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver. Silverback Therapeutics, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time